#United States #New York #Class Action #Gross Law Firm #UroGen Pharma

UroGen Pharma Ltd. Faces Class Action Lawsuit

On June 9, 2025, The Gross Law Firm announced a class action lawsuit against UroGen Pharma Ltd. (NASDAQ: URGN), signaling significant legal concerns that may impact shareholders. This report serves as a crucial notice for individuals who acquired shares from July 27, 2023, to May 15, 2025, to ensure they understand their rights during this legal proceeding.

Background of the Lawsuit

The lawsuit alleges that UroGen violated securities laws by issuing misleading statements about its products, particularly regarding its lead pipeline product, UGN-102. Shareholders are encouraged to contact The Gross Law Firm for assistance, especially if they wish to seek lead plaintiff status. Importantly, becoming a lead plaintiff is not a prerequisite for participating in potential recovery from the class action.

Allegations Against UroGen

Central to the lawsuit are several critical claims:
1. Misleading Statements: It is alleged that the company made materially false statements about the effectiveness of UGN-102 when they failed to disclose that the ENVISION clinical study was inadequately designed to demonstrate its efficacy. The absence of a concurrent control arm raises significant concerns about the reliability of the results presented.
2. Failure to Address FDA Concerns: The complaint maintains that UroGen ignored warnings from the FDA regarding the study design, leading to skepticism about the application for New Drug Approval (NDA) for UGN-102. There were reports indicating that because of these issues, the NDA might not be approved, posing a risk to the company's business outlook.
3. Misleading Outlook: Throughout the class period, UroGen's management allegedly made optimistic statements regarding the company's future, operations, and product prospects, despite internal knowledge that their claims may not be grounded in reality.

Important Deadlines and Actions

The deadline for shareholders to join this class action as lead plaintiff is set for July 28, 2025. To safeguard their interests, affected shareholders should promptly register their information via the link provided by The Gross Law Firm. This action will also enroll them in a portfolio monitoring software that provides status updates on the legal proceedings.

Beyond financial implications, the Gross Law Firm is dedicated to advocating for the rights of investors and holding UroGen accountable for any deceptive practices that may have led to financial losses. They emphasize no cost or obligation for shareholders to participate in this case, highlighting their role as advocates for investor rights.

Why Choose Gross Law Firm?

The Gross Law Firm is well-known for its commitment to upholding investor rights and ensuring accountability among publicly traded companies. With a reputation for fighting against deceitful practices, they aim to recover losses for investors affected by misleading company endorsements and practices that inflate stock prices unlawfully.

Conclusion

The class action against UroGen Pharma Ltd. is a serious development for shareholders, signaling potential risks associated with their investments. Shareholders during the stipulated class period must take immediate action, not only to protect their investments but also to contribute to a precedent for corporate accountability in the pharmaceuticals sector. For further inquiries, shareholders can reach out to The Gross Law Firm directly at their New York office.

For more information, interested parties can visit Gross Law Firm's contact page for a detailed submission form and additional assistance on this case.